Table 2.
Clinical features of FMF disease and current treatment in patients with COVID-19.
| The disease duration, years, median (IQR, min-max) | 10 (10) (min-max:1–49) |
|---|---|
| MEVF gene analysesa, n (%) | |
| M694V mutation | 45 (76) |
| V726A mutation | 8 (13.5) |
| M680I mutation | 13 (22) |
| Characteristics of FMF attacks, n (%) | |
| Fever | 52 (71.2) |
| Peritonitis | 59 (80.8) |
| Pleuritis | 38 (52) |
| Arthritis | 32 (43.8) |
| Skin rash (erysipelas-like erythema) | 23 (31.5) |
| Standing myalgia | 29 (39.7) |
| Amyloidosis, n (%) | 14 (19.2) |
| Medications | |
| Colchicine, n (%) | 73 (100) |
| Doses 0.5 mg/day | 1 (1.3) |
| 1 mg/day | 29 (39.7) |
| 1.5 mg/day | 25 (34.2) |
| ≥2 mg/day | 18 (24.6) |
| IL-1 antagonists, n (%) | |
| Anakinra | 14 (19.2) |
| Canakinumab | 3 (4.1) |
| Tocilizumab, n (%) | 1 (1.3) |
| Disease activityb, remission, n (%) | 46 (64) |
a
MEVF gene analyses were available for 59 patients.
b
Disease activity before the infection was available for 72 patients.